Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Buprenorphine→

Buprenorphine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
52485-79-7
Molecular formula
C29H41NO4
Molecular weight
467.6 g/mol
Drug class
Partial Opioid AgonistOpioid Antagonist
Mechanism of action
Partial Opioid Agonists [MoA]
Indications / reported uses
  • Heroin Dependence
  • Pain
  • opioid dependence and is preferred for induction
  • severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate release opioids
  • severe and persistent pain that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids

Sources: FDA product labels (openFDA) · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Buprenorphine Environmental Risk Assessment (ERA) (the Buprenorphine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.